PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc. (Nasdaq: PRDS) is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, with a lead program targeting SARS-CoV-2. The company entered the public markets through a business combination with LifeSci Acquisition 2 Corp, a blank-check company sponsored by LifeSci Capital, which completed its IPO in 2021 targeting the healthcare and life sciences sector. An 8-K filed December 30, 2021 documented the closing of that merger, marking PRDS as a newly listed Nasdaq company. For comprehensive filing histories, sponsor profiles, and deal analytics on Pardes Biosciences and thousands of other SPAC transactions, sign up for full data access at SpacDesk.